Literature DB >> 23787367

An international serum standard for application in assays to detect human complement activation products.

Grethe Bergseth1, Judith K Ludviksen, Michael Kirschfink, Patricia C Giclas, Bo Nilsson, Tom E Mollnes.   

Abstract

The importance of the complement system in clinical medicine has become evident during the last decades and complement therapeutics has now reached the clinic. Thus, there is an increased interest in and need for assays to evaluate complement activity and dysfunction. Pathologically increased complement activation can indirectly be evaluated by quantification of complement components, but in order to exactly measure such activation, assays for quantification of products formed during activation are required. Progress in this field is hampered by lack of standardization. Therefore, members of the International Complement Standardization Committee, a joint initiative of the International Complement Society and the International Union of Immunological Societies (IUIS), prepared a defined standard for application in assays for complement activation products. We here report on the production and properties of this International Complement Standard #2 (ICS#2). ICS#2 was made from a pool of sera from healthy blood donors (ICS#1) that was activated with a combination of heat-aggregated IgG and zymosan, and subsequently stabilized by adding EDTA and nafamostat mesylate. The protocol was optimized to make the standard applicable in the following activation product assays: C1rs-C1-inhibitor complexes, C4a, C4bc, C4d, Bb, C3bBbP, C3a, C3bc, C3dg, C5a and the soluble terminal C5b-9 complement complex (SC5b-9, TCC). ICS#2 was defined as containing 1000 complement activation units (CAU)/mL for all activation products measured. All activation products were stable after 10 times thawing and freezing and most of the activation products were stable during storage at 4°C for up to 21 days. ICS#2 was produced large-scale and is considered a valuable tool for standardization, calibration and reference control for complement activation assays, providing the necessary prerequisite for quality assessments between complement laboratories.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activation products; Assay; Complement; Standard

Mesh:

Substances:

Year:  2013        PMID: 23787367     DOI: 10.1016/j.molimm.2013.05.221

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  72 in total

1.  Eculizumab in Pediatric Dense Deposit Disease.

Authors:  Michiel J S Oosterveld; Mark R Garrelfs; Bernd Hoppe; Sandrine Florquin; Joris J T H Roelofs; L P van den Heuvel; Kerstin Amann; Jean-Claude Davin; Antonia H M Bouts; Pietrik J Schriemer; Jaap W Groothoff
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-27       Impact factor: 8.237

Review 2.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

3.  A novel method for direct measurement of complement convertases activity in human serum.

Authors:  A M Blom; E B Volokhina; V Fransson; P Strömberg; L Berghard; M Viktorelius; T E Mollnes; M López-Trascasa; L P van den Heuvel; T H Goodship; K J Marchbank; M Okroj
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

4.  The anti-inflammatory effect of combined complement and CD14 inhibition is preserved during escalating bacterial load.

Authors:  Kjetil H Egge; Andreas Barratt-Due; Stig Nymo; Julie K Lindstad; Anne Pharo; Corinna Lau; Terje Espevik; Ebbe B Thorgersen; Tom E Mollnes
Journal:  Clin Exp Immunol       Date:  2015-07-19       Impact factor: 4.330

5.  Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo.

Authors:  Elena B Volokhina; Grethe Bergseth; Nicole C A J van de Kar; Lambertus P van den Heuvel; Tom Eirik Mollnes
Journal:  Blood       Date:  2015-07-09       Impact factor: 22.113

6.  Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes.

Authors:  Peter Popp Wibroe; Aaron C Anselmo; Per H Nilsson; Apoorva Sarode; Vivek Gupta; Rudolf Urbanics; Janos Szebeni; Alan Christy Hunter; Samir Mitragotri; Tom Eirik Mollnes; Seyed Moein Moghimi
Journal:  Nat Nanotechnol       Date:  2017-04-10       Impact factor: 39.213

7.  Plasma levels of soluble membrane attack complex are elevated despite viral suppression in HIV patients with poor immune reconstitution.

Authors:  T N Schein; T E Blackburn; S L Heath; S R Barnum
Journal:  Clin Exp Immunol       Date:  2019-09-08       Impact factor: 4.330

8.  Systemic inflammation in acute intermittent porphyria: a case-control study.

Authors:  E Storjord; J A Dahl; A Landsem; H Fure; J K Ludviksen; S Goldbeck-Wood; B O Karlsen; K S Berg; T E Mollnes; E W Nielsen; O-L Brekke
Journal:  Clin Exp Immunol       Date:  2016-12-15       Impact factor: 4.330

9.  Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis.

Authors:  Ravi Shankar Keshari; Robert Silasi; Narcis Ioan Popescu; Maulin Mukeshchandra Patel; Hala Chaaban; Cristina Lupu; K Mark Coggeshall; Tom Eirik Mollnes; Steven J DeMarco; Florea Lupu
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-18       Impact factor: 11.205

10.  Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome.

Authors:  Lambertus van den Heuvel; Kristian Riesbeck; Omaima El Tahir; Valentina Gracchi; Mariann Kremlitzka; Servaas A Morré; A Marceline van Furth; Birendra Singh; Marcin Okrój; Nicole van de Kar; Anna M Blom; Elena Volokhina
Journal:  J Hum Genet       Date:  2017-11-13       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.